MEI is developing a range of anti-cancer therapies that represents the next generation of oncology drugs - multiple signal transduction regulators (abbreviated as 'MSTRs') that reach to the heart of the cancer process.

The source of this new range of drugs is a family of chemicals, discovered by pharmaceutical company Novogen, that act against the fundamentals of the cancer process. Using this single technology platform, MEI is developing a number of drugs with novel actions against a range of different cancer types.

The first of these drugs - Phenoxodiol - has advanced to Phase II clinical studies.

Go to Newsroom for the latest announcement and clinical trials for a listing of the current trials.